Skip to main content
Top
Published in: Clinical Rheumatology 3/2018

01-03-2018 | Original Article

Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study

Authors: Usanee Damrongpipatkul, Kanokporn Oranratanachai, Nuntana Kasitanon, Salita Wuttiplakorn, Worawit Louthrenoo

Published in: Clinical Rheumatology | Issue 3/2018

Login to get access

Abstract

Posterior reversible encephalopathy syndrome (PRES) in patients with systemic lupus erythematosus (SLE) has been recognized increasingly. This study aimed to determine the prevalence, clinical features, brain imaging findings, outcomes, and associated factors of PRES in Thai SLE patients. SLE patients with PRES were identified from the lupus cohort of Chiang Mai University. Controls were SLE patients with a hospital number close to and actually had SLE diagnosis within 5 years of the case (case:control ratio = 1:4). Of 1,332 SLE patients, 30 episodes of PRES were identified in 24 female SLE patients (prevalence 1.80%). The mean ± SD age at SLE diagnosis and at onset of PRES was 25.02 ± 13.78 and 28.31 ± 12.61 years, respectively. Seizure was the most common presenting symptom, as seen in 28 episodes, followed by acute severe headache in 17, alteration of consciousness in 17, nausea and vomiting in 10, blurred vision in 11, and hemiparesis in 3. Abrupt increase in blood pressure and active nephritis were seen in 29 and 26 of the episodes, respectively. Urine protein/creatinine ratio > 1.00 (OR 15.72, 95% CI 3.12–79.12, p = 0.001) and hemoglobin < 10 gm/dL (OR 5.12, 95% CI 1.37–19.15, p = 0.015) were associated factors for developing PRES. During the observation period, 7 patients in the PRES group and 8 in the control group died (p = 0.015). PRES was uncommon in SLE patients, but associated with a high mortality rate. Active nephritis and anemia were associated factors of PRES in Thai SLE patients.
Literature
1.
go back to reference Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F et al (2016) The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 74:41–72CrossRefPubMed Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F et al (2016) The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 74:41–72CrossRefPubMed
2.
go back to reference Lamy C, Oppenheim C, Meder JF, Mas JL (2004) Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging 14:89–96CrossRefPubMed Lamy C, Oppenheim C, Meder JF, Mas JL (2004) Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging 14:89–96CrossRefPubMed
3.
go back to reference Bartynski WS, Boardman JF (2007) Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28:1320–1327CrossRefPubMed Bartynski WS, Boardman JF (2007) Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28:1320–1327CrossRefPubMed
5.
go back to reference Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A et al (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500CrossRefPubMed Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A et al (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500CrossRefPubMed
6.
go back to reference Ishimori ML, Pressman BD, Wallace DJ, Weisman MH (2007) Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE? Lupus 16:436–443CrossRefPubMed Ishimori ML, Pressman BD, Wallace DJ, Weisman MH (2007) Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE? Lupus 16:436–443CrossRefPubMed
7.
go back to reference Barber CE, Leclerc R, Gladman DD, Urowitz MB, Fortin PR (2011) Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus. Semin Arthritis Rheum 41:353–363CrossRefPubMed Barber CE, Leclerc R, Gladman DD, Urowitz MB, Fortin PR (2011) Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus. Semin Arthritis Rheum 41:353–363CrossRefPubMed
8.
go back to reference Magnano MD, Bush TM, Herrera I, Altman RD (2006) Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 35:396–402CrossRefPubMed Magnano MD, Bush TM, Herrera I, Altman RD (2006) Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 35:396–402CrossRefPubMed
9.
go back to reference Merayo-Chalico J, Apodaca E, Barrera-Vargas A, Alcocer-Varela J, Colunga-Pedraza I, Gonzalez-Patino A et al (2016) Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study. J Neurol Neurosurg Psychiatry 87:287–294CrossRefPubMed Merayo-Chalico J, Apodaca E, Barrera-Vargas A, Alcocer-Varela J, Colunga-Pedraza I, Gonzalez-Patino A et al (2016) Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study. J Neurol Neurosurg Psychiatry 87:287–294CrossRefPubMed
10.
go back to reference Kur JK, Esdaile JM (2006) Posterior reversible encephalopathy syndrome—an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol 33:2178–2183PubMed Kur JK, Esdaile JM (2006) Posterior reversible encephalopathy syndrome—an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol 33:2178–2183PubMed
11.
go back to reference Gatla N, Annapureddy N, Sequeira W, Jolly M (2013) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Clin Rheumatol 19:334–340CrossRefPubMed Gatla N, Annapureddy N, Sequeira W, Jolly M (2013) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Clin Rheumatol 19:334–340CrossRefPubMed
12.
go back to reference Shaharir SS, Remli R, Marwan AA, Said MS, Kong NC (2013) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: pooled analysis of the literature reviews and report of six new cases. Lupus 22:492–496CrossRefPubMed Shaharir SS, Remli R, Marwan AA, Said MS, Kong NC (2013) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: pooled analysis of the literature reviews and report of six new cases. Lupus 22:492–496CrossRefPubMed
13.
go back to reference Varaprasad IR, Agrawal S, Prabu VN, Rajasekhar L, Kanikannan MA, Narsimulu G (2011) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Rheumatol 38:1607–1611CrossRefPubMed Varaprasad IR, Agrawal S, Prabu VN, Rajasekhar L, Kanikannan MA, Narsimulu G (2011) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Rheumatol 38:1607–1611CrossRefPubMed
14.
go back to reference Jung SM, Moon SJ, Kwok SK, JH J, Park KS, Park SH et al (2013) Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome. Lupus 22:885–891CrossRefPubMed Jung SM, Moon SJ, Kwok SK, JH J, Park KS, Park SH et al (2013) Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome. Lupus 22:885–891CrossRefPubMed
15.
go back to reference Liu B, Zhang X, Zhang FC, Yao Y, Zhou RZ, Xin MM et al (2012) Posterior reversible encephalopathy syndrome could be an underestimated variant of “reversible neurological deficits” in systemic lupus erythematosus. BMC Neurol 12:152CrossRefPubMedPubMedCentral Liu B, Zhang X, Zhang FC, Yao Y, Zhou RZ, Xin MM et al (2012) Posterior reversible encephalopathy syndrome could be an underestimated variant of “reversible neurological deficits” in systemic lupus erythematosus. BMC Neurol 12:152CrossRefPubMedPubMedCentral
16.
go back to reference Lai CC, Chen WS, Chang YS, Wang SH, Huang CJ, Guo WY et al (2013) Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65:1766–1774CrossRef Lai CC, Chen WS, Chang YS, Wang SH, Huang CJ, Guo WY et al (2013) Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65:1766–1774CrossRef
17.
go back to reference Fujieda Y, Kataoka H, Odani T, Otomo K, Kato M, Fukaya S et al (2011) Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus. Mod Rheumatol 21:276–281CrossRefPubMed Fujieda Y, Kataoka H, Odani T, Otomo K, Kato M, Fukaya S et al (2011) Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus. Mod Rheumatol 21:276–281CrossRefPubMed
18.
go back to reference The American College of Rheumatology (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRef The American College of Rheumatology (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRef
19.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed
20.
go back to reference Uribe AG, Vila LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcon GS (2004) The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 31:1934–1940PubMed Uribe AG, Vila LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcon GS (2004) The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 31:1934–1940PubMed
21.
go back to reference Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 64:159–168CrossRef Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 64:159–168CrossRef
23.
go back to reference Ferreira TS, Reis F, Appenzeller S (2016) Posterior reversible encephalopathy syndrome and association with systemic lupus erythematosus. Lupus 25:1369–1376CrossRefPubMed Ferreira TS, Reis F, Appenzeller S (2016) Posterior reversible encephalopathy syndrome and association with systemic lupus erythematosus. Lupus 25:1369–1376CrossRefPubMed
24.
go back to reference Jabrane M, Ait Lahcen Z, Fadili W, Laouad I (2015) A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide. Rheumatol Int 35:935–938CrossRefPubMed Jabrane M, Ait Lahcen Z, Fadili W, Laouad I (2015) A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide. Rheumatol Int 35:935–938CrossRefPubMed
25.
go back to reference Chennareddy S, Adapa R, Kishore BK, Rajasekhar L (2013) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus following methylprednisolone: report of two cases. Int J Rheum Dis 16:786–788CrossRefPubMed Chennareddy S, Adapa R, Kishore BK, Rajasekhar L (2013) Posterior reversible encephalopathy syndrome in systemic lupus erythematosus following methylprednisolone: report of two cases. Int J Rheum Dis 16:786–788CrossRefPubMed
26.
go back to reference Jayaweera JL, Withana MR, Dalpatadu CK, Beligaswatta CD, Rajapakse T, Jayasinghe S et al (2014) Cyclophosphamide-induced posterior reversible encephalopathy syndrome (PRES): a case report. J Med Case Rep 8:442CrossRefPubMedPubMedCentral Jayaweera JL, Withana MR, Dalpatadu CK, Beligaswatta CD, Rajapakse T, Jayasinghe S et al (2014) Cyclophosphamide-induced posterior reversible encephalopathy syndrome (PRES): a case report. J Med Case Rep 8:442CrossRefPubMedPubMedCentral
27.
go back to reference Budhoo A, Mody GM (2015) The spectrum of posterior reversible encephalopathy in systemic lupus erythematosus. Clin Rheumatol 34:2127–2134CrossRefPubMed Budhoo A, Mody GM (2015) The spectrum of posterior reversible encephalopathy in systemic lupus erythematosus. Clin Rheumatol 34:2127–2134CrossRefPubMed
28.
go back to reference Baizabal-Carvallo JF, Barragan-Campos HM, Padilla-Aranda HJ, Alonso-Juarez M, Estanol B, Cantu-Brito C et al (2009) Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg 111:359–363CrossRefPubMed Baizabal-Carvallo JF, Barragan-Campos HM, Padilla-Aranda HJ, Alonso-Juarez M, Estanol B, Cantu-Brito C et al (2009) Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg 111:359–363CrossRefPubMed
29.
go back to reference Sutton EJ, Davidson JE, Bruce IN (2013) The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 43:352–361CrossRefPubMed Sutton EJ, Davidson JE, Bruce IN (2013) The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 43:352–361CrossRefPubMed
Metadata
Title
Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study
Authors
Usanee Damrongpipatkul
Kanokporn Oranratanachai
Nuntana Kasitanon
Salita Wuttiplakorn
Worawit Louthrenoo
Publication date
01-03-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3892-2

Other articles of this Issue 3/2018

Clinical Rheumatology 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.